Crescent Biopharma (C68) Price & Analysis

2 Followers

C68 Stock Chart & Stats

€13.70

€1.10(8.46%)

At close: Jul 24 4:00 PM EDT

€13.70

€1.10(8.46%)

Day’s Range― - ―

52-Week Range€6.70 - €22.80

Previous CloseN/A

Volume0.00

Average Volume (3M)13.00

Market Cap

€391.37M

Enterprise Value€383.42M

Total Cash (Recent Filing)€171.59M

Total Debt (Recent Filing)€1.44M

Price to Earnings (P/E)―

Beta0.66

Next Earnings

Nov 05, 2026

EPS Estimate

-0.58

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-6.72

Shares Outstanding37,143,940

10 Day Avg. Volume7

30 Day Avg. Volume13

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.61

Price to Sales (P/S)11.39

P/FCF Ratio-0.86

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€27.46

Price Target Upside100.47% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-2.48

Revenue Forecast (FY)€1.67M

Bulls Say, Bears Say

Bulls Say

Clinical Pipeline ProgressCompletion of dose escalation and enrollment across global ASCEND cohorts moves CR-001 beyond early development and creates multiple upcoming clinical readouts. If data support activity and safety, the program could broaden indications and improve the company’s development prospects over the next several quarters.

Pipeline DiversificationFDA clearance for CR-002 and planned global APOLLO enrollment broaden the portfolio beyond CR-001, while multiple tumor settings create several development paths. This diversification can reduce reliance on one candidate and build a more substantial oncology pipeline, although outcomes remain unproven.

Low Financial LeverageVery low debt reduces near-term balance-sheet pressure and limits interest-related demands on a company funding research and clinical programs. This provides more financial flexibility than a highly leveraged structure, although it does not eliminate the need to finance ongoing operating losses.

Bears Say

Severe UnprofitabilityRevenue remains small relative to operating costs, producing very large EBIT and net losses. This gap indicates that the business has not yet achieved commercial scale, leaving future financial performance heavily dependent on successful development, approval, and eventual monetization of its pipeline.

Worsening Cash BurnSubstantial negative operating and free cash flow means the company is consuming capital rather than funding its activities internally. The sharp deterioration in free cash flow increases future funding needs and could constrain development pace or require additional financing if spending remains elevated.

Equity ErosionDeclining equity shows that sustained losses are reducing the capital base supporting the business. Continued erosion can weaken financial resilience over time and reduce flexibility to fund clinical programs internally, even though current debt levels are low and balance-sheet leverage remains conservative.

Crescent Biopharma News

Crescent Biopharma completes dose escalation in ASCEND trial of CR-001

Crescent Biopharma (CBIO) announced clinical pipeline momentum, including enrolling patients in cohorts combining CR-001, a PD-1 x VEGF...

3d ago

CBIO

Crescent Biopharma upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Crescent Biopharma (CBIO) to Buy from Neutral with a $36 price target The shares offer...

13d ago

CBIO

Crescent Biopharma announces FDA clearance of CR-002 IND application

Crescent Biopharma (CBIO) announced that the FDA has cleared its investigational new drug, or IND, application for CR-002,...

14d ago

CBIO

Crescent Biopharma advances oncology pipeline and ADC programs

Crescent Biopharma ( ($CBIO) ) has shared an announcement. On October 15, 2026, Crescent Biopharma reported progress across...

3d ago

CBIO

Analyst Backs Crescent Biopharma With Buy Rating on Advancing ADC Pipeline and Strong Cash Runway

LifeSci Capital analyst Charles Zhu maintained a Buy rating on Crescent Biopharma today and set a price target...

3M ago

CBIO

Crescent Biopharma reports Q2 EPS (74c), consensus (64c)

“We have continued to demonstrate exceptional execution and are on track for multiple key clinical data readouts across...

3M ago

CBIO

Crescent Biopharma, Inc. (CBIO) Q2 Earnings Cheat Sheet

Crescent Biopharma, Inc. (CBIO) is scheduled to report 2nd quarter earnings on 07/30/2026. Regarding Q2 estimates, Wall Street...

3M ago

CBIO

Travelers, TransDigm, Cytokinetics, Global-e, Crescent Shock Moves

Insiders have been trading these 5 stocks: (($TRV)), (($TDG)), (($CYTK)), (($GLBE)) and (($CBIO)). Here is a breakdown of...

3M ago

TDG

TRV

Fourteen new option listings and one option delisting on July 22nd

New option listings for July 22nd include Tradr 2X Short AAOI Daily ETF (AAOZ), Alpha Cognition Inc (ACOG),...

3M ago

ACOG

ARTV

Crescent Biopharma 8.095M share Spot Secondary priced at $14.50

Jefferies, TD Cowen, Guggenheim and Cantor Fitzgerald acted as joint book running managers for the offering. Published first...

3M ago

CBIO

Crescent Biopharma files ordinary shares offering, no amount given

Jefferies, TD Cowen, Guggenheim, and Cantor are acting as joint book-running managers. LifeSci Capital is acting as a...

3M ago

CBIO

BTIG says others may be interested in Apogee Therapeutics

BTIG analyst Julian Harrison says AbbVie (ABBV) can leverage its existing dermatology channels and compete in atopic dermatitis...

4M ago

JNJ

NVS

Campbell, Crescent, Cardiff, Sherwin, Take-Two Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($CPB) ), ( ($CBIO) ), ( ($CRDF) ), ( ($SHW)...

4M ago

CPB

SHW

Crescent Biopharma shareholders back directors, pay and auditor

Crescent Biopharma ( ($CBIO) ) just unveiled an update. On June 2, 2026, Crescent Biopharma, Inc. held its...

5M ago

CBIO

C68 FAQ

What was Crescent Biopharma’s price range in the past 12 months?

Crescent Biopharma lowest stock price was €6.70 and its highest was €22.80 in the past 12 months.

What is Crescent Biopharma’s market cap?

Crescent Biopharma’s market cap is €391.37M.

When is Crescent Biopharma’s upcoming earnings report date?

Crescent Biopharma’s upcoming earnings report date is Nov 05, 2026 which is in 17 days.

How were Crescent Biopharma’s earnings last quarter?

Crescent Biopharma released its earnings results on Jul 30, 2026. The company reported -€0.634 earnings per share for the quarter, missing the consensus estimate of -€0.631 by -€0.003.

Is Crescent Biopharma overvalued?

According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Crescent Biopharma pay dividends?

Crescent Biopharma does not currently pay dividends.

What is Crescent Biopharma’s EPS estimate?

Crescent Biopharma’s EPS estimate is -0.58.

How many shares outstanding does Crescent Biopharma have?

Crescent Biopharma has 37,143,940 shares outstanding.

What happened to Crescent Biopharma’s price movement after its last earnings report?

Crescent Biopharma reported an EPS of -€0.634 in its last earnings report, missing expectations of -€0.631. Following the earnings report the stock price went down -11.765%.

Which hedge fund is a major shareholder of Crescent Biopharma?

Currently, no hedge funds are holding shares in DE:C68

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Crescent Biopharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

-97.77%

Trailing 12-Months

Asset Growth

16.09%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Crescent Biopharma

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Crescent Biopharma (C68) Earnings & Revenues

Historic Earnings Reports

C68 Stock 12 Month Forecast

Average Price Target

€27.46

▲(100.47% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","20":"€20","33":"€33","13.5":"€13.5","26.5":"€26.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32.1004674,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€32.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.46373322,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€27.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.07535055,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€24.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13.5,20,26.5,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.1,13.638497492307692,15.176994984615384,16.715492476923075,18.25398996923077,19.79248746153846,21.330984953846155,22.869482446153846,24.407979938461537,25.946477430769228,27.48497492307692,29.02347241538461,30.56196990769231,{"y":32.1004674,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.1,13.281825632307692,14.463651264615384,15.645476896923078,16.82730252923077,18.009128161538463,19.190953793846155,20.372779426153848,21.55460505846154,22.736430690769232,23.918256323076925,25.100081955384617,26.28190758769231,{"y":27.46373322,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.1,13.02118081153846,13.942361623076923,14.863542434615384,15.784723246153845,16.705904057692308,17.62708486923077,18.54826568076923,19.469446492307693,20.390627303846152,21.311808115384615,22.232988926923078,23.15416973846154,{"y":24.07535055,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.174,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.4,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >